Stay updated with breaking news from டார்சி ராபின்சன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stolen car torched in Burnaby, fire spreads into brush - BC News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.
VBI Vaccines Inc.: Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Everest Medicines Announces Amended Agreement with Spero Therapeutics Spero will assign relevant SPR206 patents to Everest Medicines in Greater China, South Korea and certain Southeast Asian countries News provided by Share this article Share this article SHANGHAI, Jan. 18, 2021 /PRNewswire/ Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that under an amended license agreement with Spero Therapeutics, the relevant patents for SPR206 will be assigned to Everest in Greater China, South Korea and certain Southeast Asian countries (the Territory ). The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. ....
Share this article Share this article SHANGHAI, Jan. 6, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Breast Cancer is Singapore s number one leading cause of cancer death in women and TNBC accounts for 15-20% of all breast cancer in Singapore. This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest s licensed territory, which also includes Greater China, South Korea, and certain addi ....
Share this article Share this article SHANGHAI, Jan. 6, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People s Republic of China has approved a Clinical Trial Application (CTA) for sacituzumab govitecan-hziy for the treatment of patients with metastatic urothelial cancer (mUC). With this CTA, Everest Medicines plans to enroll patients in China as part of the Phase 3, global, multicenter, open-label randomized controlled TROPiCS-04 trial. The trial will evaluate sacituzumab govitecan-hziy compared with standard of care chemotherapeutic options in subjects with metastatic or locally advanced unresectable urothelial cancer who have progresse ....